The Female Health Co. (FHC), of Chicago, and Aspen Park Pharmaceuticals Inc. (APP), of New York, said the FDA agreed to an expedited regulatory pathway for APP's tamsulosis DRS (delayed-release sachet) for benign prostatic hyperplasia under the 505(b)(2) pathway. A three-week bioequivalence study will be initiated in the fourth quarter, with plans to submit an NDA in 2017. FHC and APP inked a merger agreement earlier this year.